Pluri (NASDAQ:PLUR) Shares Up 4.7%
Pluri (NASDAQ:PLUR) Shares Up 4.7%
Pluri Inc. (NASDAQ:PLUR – Get Rating)'s share price shot up 4.7% on Thursday . The stock traded as high as $0.92 and last traded at $0.91. 111,089 shares were traded during trading, a decline of 76% from the average session volume of 457,724 shares. The stock had previously closed at $0.87.
纳斯达克:PLUR-GET评级公司股价周四飙升4.7%,盘中一度涨至0.92美元,最新报0.91美元。盘中成交量为111,089股,较457,724股的平均成交量下降了76%。该股此前收盘报0.87美元。
Pluri Stock Performance
普鲁里股票表现
The company has a debt-to-equity ratio of 0.77, a current ratio of 9.91 and a quick ratio of 9.91. The business's 50 day simple moving average is $0.76.
该公司的债务权益比为0.77,流动比率为9.91,速动比率为9.91。该业务的50日简单移动均线切入位为0.76美元。
Institutional Trading of Pluri
普鲁里的机构交易
Hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Pluri in the 3rd quarter worth $28,000. Values First Advisors Inc. bought a new stake in shares of Pluri in the 3rd quarter worth $38,000. Green Alpha Advisors LLC bought a new stake in shares of Pluri in the 3rd quarter worth $44,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Pluri in the 3rd quarter worth $81,000. Institutional investors own 8.75% of the company's stock.
对冲基金和其他机构投资者最近调整了对该公司的持股。简街集团在第三季度购买了价值2.8万美元的Pluri新股。Values First Advisors Inc.在第三季度购买了价值3.8万美元的Pluri新股。Green Alpha Advisors LLC在第三季度购买了价值44,000美元的Pluri新股。最后,复兴科技有限责任公司在第三季度购买了价值8.1万美元的Pluri新股。机构投资者持有该公司8.75%的股份。
About Pluri
关于Pluri
Pluri Inc, a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation.
Pluri Inc.是一家生物技术公司,专注于开发基于胎盘的细胞治疗产品,用于治疗炎症、肌肉损伤和血液疾病。该公司开发以胎盘扩大(PLX)为基础的细胞治疗产品,包括针对髋部骨折手术后肌肉恢复的PLX-PAD处于第三阶段临床试验;与特拉维夫Sourasky医学中心合作治疗激素难治性移植物抗宿主疾病的I/II阶段临床试验;以及治疗与新冠肺炎相关的急性呼吸窘迫综合征的第二阶段临床试验和骨髓移植后不完全恢复的第一阶段临床试验。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Pluri (PLUR)
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- 免费获取StockNews.com关于Pluri的研究报告(PLUR)
- 这就是为什么达科电子在一天内下跌了40%
- 是时候在Gamestop上认输了吗?
- 为什么你应该避免Carvana,即使它可以避免破产
- 投资者是否听到了Spotify下跌趋势的终结?
- 美联储轴心的问题不是是否,而是何时,这是为什么
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pluri Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pluri和相关公司的最新新闻和分析师评级的每日简要摘要。